PDS BIOTECHNOLOGY CORP (PDSB)

Company Profile

PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. The company is headquartered in Princeton, New Jersey and currently employs 26 full-time employees. The company went IPO on 2015-10-01. The firm is developing a pipeline of targeted immunotherapies for cancer and infectious diseases based on its Versamune, Versamune plus PDS0301, and Infectimune T cell-activating platforms. Its lead clinical candidate, PDS0101, is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. PDS0101, has demonstrated the ability to reduce tumors and stabilize disease in combination with approved and investigational therapeutics in patients with a range of HPV16-associated cancers. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration and longevity of T cells in the tumor microenvironment. PDS0102, PDS0103, PDS0104, PDS0201, PDS0202, and PDS0203 are also in its pipeline of Versamune and Infectimune-based therapies.

Company Info

PDS BIOTECHNOLOGY CORP

303A College Road East

Princeton NEW JERSEY 07932

P: 18002083343

CEO: Frank Bedu-Addo

Employees: 26

Website: https://www.pdsbiotech.com